Theravance Biopharma (TBPH) Assets Average (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Assets Average data on file, last reported at $478.9 million in Q1 2026.

• Assets Average for Q1 2026 came in at $478.9 million, up 37.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $478.9 million (up 37.28% YoY), and the FY2025 annual result was $419.9 million, up 14.07% from the prior year.
• Assets Average grew to $478.9 million in Q1 2026 per TBPH's latest filing, from $450.5 million in the prior quarter.
• Over five years, Assets Average peaked at $685.4 million in Q4 2022 and troughed at $348.9 million in Q1 2025.
• A 5-year average of $435.6 million and a median of $397.8 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2023: Assets Average jumped 76.22% in 2022, then plunged 41.97% in 2023.
• A 5-year view of Assets Average shows it stood at $685.4 million in 2022, then plunged by 41.97% to $397.8 million in 2023, then decreased by 10.72% to $355.1 million in 2024, then gained by 26.86% to $450.5 million in 2025, then rose by 6.31% to $478.9 million in 2026.
• Business Quant data shows TBPH's Assets Average at $478.9 million in Q1 2026, $450.5 million in Q4 2025, and $420.7 million in Q3 2025.